Dive Brief:
- Mature biotechnology companies in Massachusetts are drawing the lion’s share of both private and public investment in 2026, according to an industry report published Tuesday by MassBio, the trade association representing the state’s biopharmaceutical firms.
- Drugmakers based in Massachusetts secured almost $3.5 billion in venture funding in the first half of 2026, a 25% increase over the same period in 2025, the report said. And eight Boston-area biotechs priced an initial public offering between January and July, including Parabilis Medicines, which broke a sector record for most cash raised in an IPO.
- But MassBio also noted that the numbers displayed a widening funding gap among startups, as the average seed round total fell to an average of $4.65 million while the mean Series A funding ballooned to nearly $80 million. The group is also tracking the fast ascent of China’s biotech ecosystem, finding that the country’s drug pipeline grew 36.2% year over year to surpass Europe for the first time. By comparison, the U.S. drug pipeline was nearly flat while Massachusetts’ climbed by 9.2%.
Dive Insight:
The biotech sector has largely recovered since bottoming out in 2022. But even with record-setting IPOs, a rebound in venture funding and a massive surge for the XBI — an exchange-traded fund closely correlated with the sector’s health — many young companies are being left out.
By and large, the sector’s top investors have shifted their sights to more ready-made drug prospects they can quickly advance. They’re more reticent to join seed rounds, leading MassBio to warn in its report that its “biggest concern” is the “earliest startups with the riskiest science.”
To get that kind of venture support, founders have to prove “novelty, commercializability and confidence in leadership,” said Ben Bradford, MassBio’s head of external affairs, in an interview.
“Importantly, a healthy ecosystem needs this renewed momentum to also reach the front end of the pipeline, where new companies are formed and the next wave of promising science is born,” Kendalle Burlin O’Connell, MassBio’s president, said in a statement.
That ecosystem might also need new tools to better compete with China. Licensing deals with China-based biotechs have skyrocketed over the last few years, shifting the world’s pharmaceutical pipeline and pressuring young companies in the U.S.
MassBio’s inclusion this year, for the first time, of a “China Watch” section in its report was a testament to that shift. In it, the organization tallied $79 billion in total proceeds related to licensing deals for China-discovered drugs last year, compared to just $1 billion in 2019. China also now runs more early-stage clinical trials than any other geography analyzed by the report.
”We’re far from losing, but we’re treading water at a time when an adversary is swimming laps,” Burlin O’Connell said in the report.
The issue has fragmented the industry. Some believe deals should be curbed, while others argue controls might cause more harm than good. Legislation so far is in its early stages, with efforts to add biotechnology to the COINS Act — and place greater scrutiny on these alliances — not yet put into law. Efforts to speed up drug research in the U.S. are also still in the planning phase.
MassBio has voiced its support for such programs. Many in the industry have turned to China for licensing, clinical testing and manufacturing not necessarily because of cost, but because of speed, Bradford said.
“The FDA was created when innovation was happening within the four walls at large pharma. That's not how it happens anymore,” he said. “It’s happening at small biotechs who don't have large regulatory teams or budgets to decipher unclear messaging or who have to compete with pharma for access at the FDA.”